Literature DB >> 18939908

HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Alan T Remaley1, Marcelo Amar, Dmitri Sviridov.   

Abstract

HDL-replacement therapy is a promising new treatment strategy involving the acute administration of HDL to rapidly stabilize patients at imminent risk for developing a myocardial infarction, such as those with acute coronary syndrome. This review will first focus on the anti-atherogenic mechanisms for HDL, such as the stimulation of the reverse cholesterol transport pathway, and then discuss the other potential beneficial biological effects of HDL on atherosclerosis. The various types of HDL-replacement therapies that are being investigated and developed will be reviewed and ongoing clinical trials and other possible clinical indications for HDL-replacement therapy besides the prevention of myocardial infarction will also be described. Finally, HDL-replacement therapy will be put into perspective by summarizing the current gaps in our knowledge of HDL metabolism and identifying challenges for future research in this area.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18939908      PMCID: PMC4164165          DOI: 10.1586/14779072.6.9.1203

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  140 in total

1.  Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.

Authors:  C R Sirtori; L Calabresi; G Franceschini; D Baldassarre; M Amato; J Johansson; M Salvetti; C Monteduro; R Zulli; M L Muiesan; E Agabiti-Rosei
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

Review 2.  Scavenger receptor BI and cholesterol trafficking.

Authors:  D L Williams; M A Connelly; R E Temel; S Swarnakar; M C Phillips; M de la Llera-Moya; G H Rothblat
Journal:  Curr Opin Lipidol       Date:  1999-08       Impact factor: 4.776

3.  Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.

Authors:  B Föger; M Chase; M J Amar; B L Vaisman; R D Shamburek; B Paigen; J Fruchart-Najib; J A Paiz; C A Koch; R F Hoyt; H B Brewer; S Santamarina-Fojo
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

4.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Authors:  Laurent Yvan-Charvet; Mollie Ranalletta; Nan Wang; Seongah Han; Naoki Terasaka; Rong Li; Carrie Welch; Alan R Tall
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo.

Authors:  P G Lerch; M O Spycher; J E Doran
Journal:  Thromb Haemost       Date:  1998-08       Impact factor: 5.249

6.  Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties.

Authors:  Jonas Heilskov Graversen; Jacob Marsvin Laurberg; Mikkel Holmen Andersen; Erling Falk; John Nieland; Jesper Christensen; Michael Etzerodt; Hans Christian Thøgersen; Søren Kragh Moestrup
Journal:  J Cardiovasc Pharmacol       Date:  2008-02       Impact factor: 3.105

7.  Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice.

Authors:  Eugene Trogan; Jonathan E Feig; Snjezana Dogan; George H Rothblat; Véronique Angeli; Frank Tacke; Gwendalyn J Randolph; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-01       Impact factor: 11.205

8.  Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors.

Authors:  Chun-Lin Chen; Shuan Shian Huang; Jung San Huang
Journal:  J Cell Physiol       Date:  2008-04       Impact factor: 6.384

9.  Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries.

Authors:  Sanjay Kaul; Vladimir Rukshin; Raul Santos; Babak Azarbal; Charles L Bisgaier; Jan Johansson; Vivian T Tsang; Kuang-Yuh Chyu; Bojan Cercek; James Mirocha; Prediman K Shah
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

Review 10.  Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.

Authors:  Laura Calabresi; Cesare R Sirtori; Rodolfo Paoletti; Guido Franceschini
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

View more
  41 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

3.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

4.  A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.

Authors:  Ulrike Schueler; Christine Kaneski; Alan Remaley; Stephen Demosky; Nancy Dwyer; Joan Blanchette-Mackie; John Hanover; Roscoe Brady
Journal:  JIMD Rep       Date:  2015-12-19

5.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

6.  Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?

Authors:  A T Remaley
Journal:  J Lipid Res       Date:  2013-10-21       Impact factor: 5.922

7.  Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter.

Authors:  D O Sviridov; I Z Ikpot; J Stonik; S K Drake; M Amar; D O Osei-Hwedieh; G Piszczek; S Turner; A T Remaley
Journal:  Biochem Biophys Res Commun       Date:  2011-06-06       Impact factor: 3.575

8.  Apolipoprotein A-II: still second fiddle in high-density lipoprotein metabolism?

Authors:  Alan T Remaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

9.  Intravenous toxicity and toxicokinetics of an HDL mimetic, Fx-5A peptide complex, in cynomolgus monkeys.

Authors:  Mohammed Bourdi; Marcelo Amar; Alan T Remaley; Pramod S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2018-10-22       Impact factor: 3.271

10.  The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Authors:  Fatiha Tabet; Alan T Remaley; Aude I Segaliny; Jonathan Millet; Ling Yan; Shirley Nakhla; Philip J Barter; Kerry-Anne Rye; Gilles Lambert
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-12-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.